Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618000126213
Ethics application status
Approved
Date submitted
18/12/2017
Date registered
30/01/2018
Date last updated
4/03/2020
Date data sharing statement initially provided
11/02/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Taking regular breaks from sitting to improve blood glucose control and blood vessel health in type 1 diabetes
Scientific title
The acute effect of breaking up sitting with brief light-intensity simple resistance activities on glycemic control, blood pressure and vascular function in individuals with type 1 diabetes
Secondary ID [1] 293628 0
Nil
Universal Trial Number (UTN)
Trial acronym
The TARGET study: Taking Regular breaks from sitting to improve Glycemic control, blood pressure and Endothelial function in type 1 diabetes,
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Type 1 diabetes 305904 0
Condition category
Condition code
Metabolic and Endocrine 305092 305092 0 0
Diabetes
Cardiovascular 305093 305093 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
In this cross-over trial, participants will complete two 8 hour laboratory-based conditions (A or B), each separated by a 3 day wash out. After a 10-hour overnight fast, participants will arrive at the laboratory at 7:30am to complete a trial condition involving: (A) UNINTERRUPTED SITTING (control condition): Participants will sit quietly in a lounge chair throughout the 8 hr period; (B) SITTING + LIGHT-INTENSITY SIMPLE RESISTANCE ACTIVITY BREAKS: Following baseline measurements and after sitting quietly for 1 hour (steady state), participants will complete a 3 min bout of simple resistance activities. The activities will be allocated into nine 20 second segments, alternating between body weight half-squats, calf raises and brief gluteal contractions in-between single leg knee raises. To ensure appropriate standardisation, participants will be supervised by trained research staff and guided through a video-led demonstration of the simple resistance activities. They will then return to the seated position. This procedure will be repeated on a further 11 occasions every 30 min for a total of 36 min of light-intensity activity. During each condition, participants will consume a standard breakfast meal after an initial 60 minute steady state period and a lunch meal at midday. Meals will be prepared according to an individual's energy requirements (33% of total daily energy requirements, Schofeld equation) and breakfast and lunch will be standardised across each laboratory-based condition.
Intervention code [1] 299889 0
Lifestyle
Intervention code [2] 299890 0
Behaviour
Comparator / control treatment
In a controlled laboratory environment, participants will complete 8 hours of prolonged sitting without breaks (only toilet breaks permitted). Participants will sit in a comfortable chair and will consume a standard breakfast meal after an initial 60 minute steady state period. Participants will also be fed a lunch meal at around midday. Meals will be prepared according to an individual's energy requirements (33% of total daily energy requirements, Schofeld equation) and breakfast and lunch will be standardised across each laboratory-based condition.
Control group
Active

Outcomes
Primary outcome [1] 304269 0
Postprandial glycemic response calculated as mean incremental area under the curve (AUC) from half-hourly venous blood sampling over the 8-hour experimental conditions
Timepoint [1] 304269 0
Blood samples for assessment of plasma glucose will be collected half-hourly until the end of the 8 hr period during each experimental conditions
Secondary outcome [1] 341437 0
Changes in resting blood pressure using automated oscillometric blood pressure monitor
Timepoint [1] 341437 0
In each experimental condition, blood pressure will be measured every hour in a resting state

Eligibility
Key inclusion criteria
Eligibility will be based on: age (25-65 years), HbA1c (less than or equal to 10%), clinical diagnosis of type 1 diabetes for more than or equal to 12 months, and treatment with insulin pump therapy for more than or equal to 6 months, with pump settings reviewed by a health professional in the previous 3 months.
Minimum age
25 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion will be based on: use of glucose-lowering agents other than insulin (e.g. metformin, GLP1 agonist); clinical history of delayed gastric emptying; having experienced a severe hypoglycaemic episode (requiring assistance) within the last 3 months; BMI <20 or >30 kg/m2; highly active (moderate intensity physical activity >300 min/wk); severe vascular complications or other conditions limiting the ability to comply with study protocols (e.g. renal impairment eGFR <60; major cardiovascular or cerebrovascular event in the previous 12 months; hospitalisation due to diabetic ketoacidosis in the previous month); fasting C-peptide greater than or equal to 50 pmol/L; current smoker; and pregnancy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
After obtaining informed consent and background information, potential participants will be screened to confirm eligibility. Once a potential subject has been deemed eligible, the subject will be randomised to the order of experimental conditions. The method for allocation concealment is closed envelopes. The allocation information will be placed in numbered envelopes (1 allocation per envelope) by an independent researcher. After a subject has been enrolled in the study, the study co-ordinators will contact an independent staff member to ask for the sequence of experimental conditions. The independent staff member will keep a log of the date and time the envelope was opened, the envelope number, the initials and gender of the participant and the order of experimental conditions. The study co-ordinator will also keep a record of this information.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The randomisation allocation sequence will be generated using computer –generated random numbers in a balanced orthogonal design
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Not applicable
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Power calculations have been made in relation to the primary outcome measures of postprandial glucose (venous collections). Based on previous studies involving overweight/obese adults and those with type 2 diabetes (references 1 and 2), we have estimated that a sample size of 30 will be needed to detect a between treatment difference of 24% in postprandial glucose (incremental AUC) with a minimum power of 80% and a probability of 0.05 (2-tailed test). As a safeguard and using our experience from previous behavioural interventions, we will over-sample to cover an estimated attrition rate of 30%. Thus, 40 participants will be recruited.

Generalized linear mixed models (GLMMs) with random intercepts will be used to evaluate the differential effects of the experimental conditions on the outcomes. Analysis of the primary outcome (glucose incremental AUC) and secondary outcome (blood pressure) will be performed blinded to the treatment allocation. All models will include fixed effects for condition, period and order and random intercepts for repeated measures. GLMMs are appropriate for correlated data (repeated measures) with various distributional assumptions and can easily accommodate missing data. A probability level of 0.05 will be adopted.

References

1. Dunstan D, et al. Breaking up prolonged sitting reduces postprandial glucose and insulin responses. Diabetes Care 2012; 35: 976-983
2. Dempsey P, et al. Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities. Diab Care. 2016;34(12):2376-82.

Recruitment
Recruitment status
Stopped early
Data analysis
Data collected is being analysed
Reason for early stopping/withdrawal
Lack of funding/staff/facilities
Participant recruitment difficulties
Date of first participant enrolment
Anticipated
1/04/2018
Actual
27/07/2018
Date of last participant enrolment
Anticipated
1/03/2020
Actual
11/07/2019
Date of last data collection
Anticipated
1/05/2020
Actual
Sample size
Target
40
Accrual to date
Final
8
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 9606 0
Baker Heart and Diabetes Institute - Melbourne
Recruitment postcode(s) [1] 18363 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 298245 0
Charities/Societies/Foundations
Name [1] 298245 0
Diabetes Australia
Country [1] 298245 0
Australia
Primary sponsor type
Individual
Name
Professor David Dunstan
Address
Physical Activity Laboratory
Baker Heart and Diabetes Institute
Level 4, Alfred Centre
99 Commercial Road
Melbourne VIC 3004
Country
Australia
Secondary sponsor category [1] 297362 0
None
Name [1] 297362 0
Address [1] 297362 0
Country [1] 297362 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 299253 0
Alfred Health Human Ethics Committee
Ethics committee address [1] 299253 0
Ethics committee country [1] 299253 0
Australia
Date submitted for ethics approval [1] 299253 0
11/01/2018
Approval date [1] 299253 0
31/01/2018
Ethics approval number [1] 299253 0
Project number 11/18

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 79798 0
Prof David Dunstan
Address 79798 0
Physical Activity Laboratory
Baker Heart and Diabetes Institute
Level 4, Alfred Centre
99 Commercial Road
Melbourne VIC 3004
Country 79798 0
Australia
Phone 79798 0
+61 3 8532 1873
Fax 79798 0
+61 3 8532 1150
Email 79798 0
David.Dunstan@baker.edu.au
Contact person for public queries
Name 79799 0
Robyn Larsen
Address 79799 0
Physical Activity Laboratory
Baker Heart and Diabetes Institute
Level 4, Alfred Centre
99 Commercial Road
Melbourne VIC 3004
Country 79799 0
Australia
Phone 79799 0
+61 3 8532 1859
Fax 79799 0
+61 3 8532 1150
Email 79799 0
Robyn.Larsen@baker.edu.au
Contact person for scientific queries
Name 79800 0
Paddy Dempsey
Address 79800 0
Physical Activity Laboratory
Baker Heart and Diabetes Institute
Level 4, Alfred Centre
99 Commercial Road
Melbourne VIC 3004
Country 79800 0
Australia
Phone 79800 0
+61 3 8532 1853
Fax 79800 0
+61 3 8532 1150
Email 79800 0
Paddy.Dempsey@baker.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Access to individual de-identified data that underlie the results reported in this article is subject to approval from the primary investigator and the Alfred Hospital Human Ethics Committee.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.